糖尿病诊断后胰腺健康的监测 (SAFE-D)
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
- attend 3 study visits over 12 months time
- provide a blood sample at each study visit
- complete an anxiety questionnaire at each visit.
研究概览
详细说明
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.
There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.
People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.
The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.
Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:SAFE-D Trial Manager
- 电话号码:+442381205154
- 邮箱:safed@soton.ac.uk
学习地点
-
-
-
Ashton-under-Lyne、英国、OL6 6HD
- 主动,不招人
- Ashton Medical Group
-
Birmingham、英国、B14 4DU
- 招聘中
- Yardley Wood Health Centre
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Bournemouth、英国、BH7 7DW
- 主动,不招人
- Bournemouth Research Hub
-
Bromborough、英国、CH62 6EE
- 招聘中
- Eastham Group Practice
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
London、英国、NW10 2PT
- 招聘中
- Willesden Medical Centre
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
London、英国、SW1P 2PF
- 招聘中
- South Westminster Centre
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
London、英国、W7 1DR
- 招聘中
- The Cuckoo Lane Practice
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Manchester、英国、M14 6WP
- 主动,不招人
- Bodey Medical Centre
-
Manchester、英国、M23 1JX
- 主动,不招人
- Bowland Medical Practice
-
Manchester、英国、M23 2SY
- 主动,不招人
- The Maples Medical Centre
-
Nottingham、英国、NG17 4JL
- 招聘中
- King's Mill Hospital (Sherwood Forest) Research Van
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Portsmouth、英国、PO1 3HN
- 主动,不招人
- Portsmouth Research Hub
-
Rossendale、英国、BB4 5SL
- 招聘中
- Hazelvalley Family Practice
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Ruislip、英国、HA4 8NX
- 招聘中
- Pembroke Centre (Hillingdon)
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Southampton、英国、SO30 3JB
- 招聘中
- Moorgreen Hospital
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Southampton、英国、SO15 33UA
- 主动,不招人
- Southampton Research Hub (Shirley Research Hub)
-
Uttoxeter、英国、ST14 8JG
- 招聘中
- Balance Street Health Centre
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Uxbridge、英国、UB8 1UW
- 招聘中
- Civic Centre
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Walsall、英国、WS6 6EW
- 招聘中
- Quinton Practice
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Weymouth、英国、DT4 0QE
- 主动,不招人
- Weymouth Research Hub
-
-
Cheshire
-
Sandbach、Cheshire、英国、CW11 1EQ
- 主动,不招人
- Ashfields Primary Care Centre
-
-
Kent
-
Maidstone、Kent、英国、ME16 9QQ
- 招聘中
- Maidstone and Tunbridge Wells NHS Trust
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
-
Leicester Forest East
-
Leicester、Leicester Forest East、英国、LE3 3LW
- 招聘中
- Forest Medical Group
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
-
Leicestershire
-
Kibworth Beauchamp、Leicestershire、英国、LE8 0LG
- 招聘中
- South Leicestershire Medical Group
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
-
Staffordshire
-
Burton-on-Trent、Staffordshire、英国、DE14 3RH
- 招聘中
- Peel Croft Surgery
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Kingswinford、Staffordshire、英国、DY6 8DN
- 招聘中
- Kingswinford Medical Practice
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Leek、Staffordshire、英国、ST13 6QR
- 招聘中
- Park Medical Centre
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Stratford-upon-Avon、Staffordshire、英国、CV37 6HJ
- 招聘中
- Trinity Court Surgery
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
-
Surrey
-
Brockham、Surrey、英国、RH3 7NJ
- 招聘中
- Brockwood Medical Practice
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Epsom、Surrey、英国、KT17 4BL
- 招聘中
- Integrated Care Partnership/ The Old Cottage Hospital
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
Warlingham、Surrey、英国、CR6 9NW
- 招聘中
- Warlingham Green Medical Practice
-
接触:
- Anson-Wisniewska
- 电话号码:02380215154
- 邮箱:safed@soton.ac.uk
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI or CT scan
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria:
- Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for or confirmed pancreatic cancer
- Under investigation/surveillance for pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- BMI > 40 at the time of consent
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Interventional
Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team. |
Avantect test |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sensitivity of the Avantect test
大体时间:The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed. |
The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
|
Specificity of the Avantect test
大体时间:The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Stage shift
大体时间:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data. Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
大体时间:The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
大体时间:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resection rate of pancreatic cancer
大体时间:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resectability
大体时间:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of pancreatic cancers deemed resectable by the study MDST. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time-to-event outcomes
大体时间:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Overall survival
大体时间:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the overall survival of study participants. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Effect of the Avantect test on state anxiety over time
大体时间:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To assess the effect of the Avantect test on state anxiety over time. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
High-grade neoplasia
大体时间:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To investigate the performance characteristics for high-grade neoplasia. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
合作者和调查者
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.